- Home
- RFM vs CSBR Comparison
RFM vs CSBR Comparison
Compare RFM & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFM
- CSBR
- Stock Information
- Founded
- RFM 2020
- CSBR 1985
- Country
- RFM United States
- CSBR United States
- Employees
- RFM N/A
- CSBR N/A
- Industry
- RFM Finance/Investors Services
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RFM Finance
- CSBR Health Care
- Exchange
- RFM Nasdaq
- CSBR Nasdaq
- Market Cap
- RFM 88.7M
- CSBR 90.0M
- IPO Year
- RFM N/A
- CSBR 1986
- Fundamental
- Price
- RFM $14.50
- CSBR $6.76
- Analyst Decision
- RFM
- CSBR Strong Buy
- Analyst Count
- RFM 0
- CSBR 1
- Target Price
- RFM N/A
- CSBR $12.00
- AVG Volume (30 Days)
- RFM 20.7K
- CSBR 12.1K
- Earning Date
- RFM 01-01-0001
- CSBR 12-10-2025
- Dividend Yield
- RFM 9.74%
- CSBR N/A
- EPS Growth
- RFM N/A
- CSBR N/A
- EPS
- RFM N/A
- CSBR 0.21
- Revenue
- RFM N/A
- CSBR $56,878,000.00
- Revenue This Year
- RFM N/A
- CSBR $7.31
- Revenue Next Year
- RFM N/A
- CSBR $12.01
- P/E Ratio
- RFM N/A
- CSBR $31.68
- Revenue Growth
- RFM N/A
- CSBR 10.11
- 52 Week Low
- RFM $12.89
- CSBR $3.96
- 52 Week High
- RFM $16.41
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- RFM 61.89
- CSBR 52.95
- Support Level
- RFM $14.25
- CSBR $6.70
- Resistance Level
- RFM $14.52
- CSBR $6.92
- Average True Range (ATR)
- RFM 0.12
- CSBR 0.19
- MACD
- RFM 0.01
- CSBR 0.02
- Stochastic Oscillator
- RFM 92.40
- CSBR 67.13
About RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.